Granted Patent B2

US 12,275,999 · App. 16/349,185 · Granted Apr 15, 2025

Inventors: Matthew B. Lee (San Jose, CA); Hedia Maamar (San Jose, CA)

Assignee: Talis Biomedical Corporation

C12Q1/689C07H21/00C07H21/04C12Q1/6844

Abstract

Claims (14)

1. A method of detecting Chlamydia trachomatis in a test sample, the method comprising:

(a) extracting nucleic acid from the test sample;

(b) amplifying a target sequence by reacting the nucleic acid extracted in step (a) with a reaction mixture comprising a strand displacement DNA polymerase and a sequence-specific primer set comprising Set-1, wherein Set-1 comprises SEQ ID NO: 3 and SEQ ID NO: 4; and

(c) detecting the presence or absence of an amplified product of step (b); wherein the presence of said amplification product is indicative of the presence of Chlamydia trachomatis in the test sample.

2. The method of claim 1 , wherein the amplification in step (b) of the target sequence is performed at between about 60° C. and about 67° C. for less than 30 minutes.

3. The method of claim 1 , wherein the amplification step is performed for less than 15 minutes.

4. The method of claim 3 , wherein the amplification step is performed for less than nine minutes.

5. The method of claim 1 , wherein detecting the presence or absence of the amplification product comprises hybridizing the amplified product with a probe comprising a polynucleotide attached to a label.

6. The method of claim 5 , wherein the probe is a molecular beacon.

7. The method of claim 1 , wherein the reaction mixture further comprises a reverse transcriptase.

8. The method of claim 1 , wherein Chlamydia trachomatis is present in the test sample at a concentration of ≤100 inclusion-forming units/ml (IFU/ml).

9. The method of claim 8 , wherein Chlamydia trachomatis is present in the test sample at a concentration of ≤50 IFU/ml.

10. The method of claim 9 , wherein Chlamydia trachomatis is present in the test sample at a concentration of ≤5 IFU/ml.

11. The method of claim 10 , wherein Chlamydia trachomatis is present in the test sample at a concentration of ≤2 IFU/ml and the amplification step is performed for less than 15 minutes.

Assignments (7)

Continuity (2)

References Cited (176)